Affimed (AFMD) Stock Price Up 2%

Affimed NV (NASDAQ:AFMD)’s share price rose 2% on Wednesday . The company traded as high as $4.25 and last traded at $4.07. Approximately 67,407 shares traded hands during trading, a decline of 85% from the average daily volume of 438,131 shares. The stock had previously closed at $3.99.

AFMD has been the subject of a number of research analyst reports. ValuEngine cut shares of Affimed from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Zacks Investment Research upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Thursday, January 3rd. Finally, BidaskClub upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $4.81.

The company has a current ratio of 3.66, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $249.56 million, a price-to-earnings ratio of -5.15 and a beta of 3.39.

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Affimed by 29.0% in the 4th quarter. Geode Capital Management LLC now owns 66,074 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 14,854 shares in the last quarter. Millennium Management LLC boosted its position in shares of Affimed by 7.2% in the 4th quarter. Millennium Management LLC now owns 3,121,914 shares of the biopharmaceutical company’s stock worth $9,709,000 after buying an additional 210,884 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in shares of Affimed in the 4th quarter worth about $36,000. Barclays PLC boosted its position in shares of Affimed by 35.6% in the 4th quarter. Barclays PLC now owns 76,959 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 20,196 shares in the last quarter. Finally, Telemetry Investments L.L.C. boosted its position in shares of Affimed by 127.9% in the 4th quarter. Telemetry Investments L.L.C. now owns 425,398 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 238,719 shares in the last quarter. Institutional investors own 41.07% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Affimed (AFMD) Stock Price Up 2%” was first reported by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2019/03/15/affimed-afmd-stock-price-up-2.html.

Affimed Company Profile (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: How to invest in a bear market

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.